Diagnosing Glanzmann’s thrombasthenia can be difficult because it requires careful analysis of medical history, family history, and clinical presentation.2 Reach out to your Novo Nordisk Representative to access a diagnostic algorithm.
Glanzmann’s thrombasthenia.
NovoSeven® RT is the only FDA-approved recombinant bypassing agent for patients with Glanzmann's thrombasthenia (GT) with refractoriness to platelet transfusions, with or without antibodies to platelets.1
Glanzmann’s thrombasthenia.
NovoSeven® RT is the only FDA-approved recombinant bypassing agent for patients with Glanzmann's thrombasthenia (GT) with refractoriness to platelet transfusions, with or without antibodies to platelets.1
Difficult to diagnose.
All bleeding episodes1,a
Proven effective in a majority of bleeds1,a
In patients with Glanzmann's thrombasthenia with refractoriness to platelet transfusions, with or without antibodies to platelets.
aMethodology: Adjudicator-assessed effectiveness of treatment regimens in patients with GT (N=218) in all severe bleeding episodes and all surgical procedures (N=1073) based on review of Glanzmann’s Thrombasthenia Registry (GTR) data unblinded to investigator-coded efficacy. Efficacy was evaluated on a 2-point scale (clinical assessment of success or failure of treatment regimen as a whole, blinded and unblinded to investigator-coded outcome) including 92 patients treated with NovoSeven® RT for 266 bleeding episodes and 77 patients treated for 160 surgical procedures.1
Data collected from the GTR and the Hemophilia & Thrombosis Research Society registry showed that 140 patients with Glanzmann's thrombasthenia received NovoSeven® RT for 518 bleeding episodes, surgeries, or traumatic injuries. In the GTR, 1 patient reported a serious adverse reaction (deep vein thrombosis) and 1 patient experienced 3 adverse reactions (nausea, headache, and dyspnea). In addition, 2 patients experienced fever and 1 patient experienced headache.1
Platelet transfusions.
Platelet transfusions are the primary treatment in patients with Glanzmann's thrombasthenia without refractoriness to platelets or in patients without platelet-specific antibodies.
bThe minimum effective dose has not been determined.
Dosing recommendation for Glanzmann's thrombasthenia.1,b
GLANZMANN’S THROMBASTHENIA
with refractoriness to platelet transfusions, with or without antibodies to platelets
90 mcg/kg
every 2-6 hours
in severe bleeding episodes requiring systemic hemostatic therapy until hemostasis is achieved
bThe minimum effective dose has not been determined.
NovoSeven® RT is manufactured for recombinant safety.
NovoSeven® RT undergoes a rigorous process to ensure safety and purity. Plus, it is the only recombinant bypassing agent not made from human serum or proteins.1 Recombinant manufacturing minimizes the possibility of viral contamination, while a <0.2% rate of thrombotic adverse events have been reported.1,3
Serious arterial and venous thrombotic events have been reported in clinical trials and postmarketing surveillance.1
![NovoSeven® RT (Coagulation Factor VIIa [Recombinant]) different vials](/content/dam/novonordisk/novosevenpro/clinicaldata/images/product-safety-profile-vials.jpg)
Room temperature stable for patients on the go.
NovoSeven® RT is room temperature stable up to 77°F.1,c
cPrior to reconstitution, store NovoSeven® RT powder and histidine diluent between 36–77°F. After reconstitution, store NovoSeven® RT either at room temperature or refrigerated for up to 3 hours. Do not freeze reconstituted NovoSeven® RT or store in syringes.
Quick reconstitution can save them time.
Every vial comes with a prefilled syringe, meaning no extra steps to fill a syringe with diluent.1,d
dCompared with reconstitution using histidine vials.
![Syringe and vial of NovoSeven® RT (Coagulation Factor VIIa [Recombinant])](/content/dam/novonordisk/novosevenpro/clinicaldata/images/product-3-step-reconstitution.jpg)
The rapid infusion time they want.
Because of its low volume, NovoSeven® RT takes 2 to 5 minutes to infuse.1
NovoSeven® RT is proven effective in perioperative management in GT patients with refractoriness to platelet transfusions, with or without antibodies to platelets.1,e
eData from a prospective, observational, multinational registry study of patients with GT.1
fData collected from the GTR and the Hemophilia & Thrombosis Research Society registry showed that 140 patients with Glanzmann's thrombasthenia received NovoSeven® RT for 518 bleeding episodes, surgeries, or traumatic injuries. In the GTR, 1 patient reported a serious adverse reaction (deep vein thrombosis) and 1 patient experienced 3 adverse reactions (nausea, headache, and dyspnea). In addition, 2 patients experienced fever and 1 patient experienced headache.1
All surgical procedures1,f
Calculate doses for your
patients living with GT with
refractoriness to platelets.
Looking for codes for
coagulation disorders?
